Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
252.860USD
-5.520-2.14%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.88BMarket Cap
613.23P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Jazz Pharmaceuticals PLC is 8.59, ranking 25 out of 155 in the Pharmaceuticals industry. The average price target is 210.00, with a high of 247.00 and a low of 147.00.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
269.204
Target Price
+5.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Jazz Pharmaceuticals PLC
JAZZ
20
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Jazz Pharmaceuticals PLC's expected revenue for the next quarter?
Jazz Pharmaceuticals PLC's expected revenue is 1.12B.
What is Jazz Pharmaceuticals PLC's price target?
Analysts forecast that Jazz Pharmaceuticals PLC's price target is USD 210.00, with the highest forecast at USD 247.00 and the lowest forecast at USD 147.00.
How have Jazz Pharmaceuticals PLCJAZZ's recent earnings per share performed?
The market expectation was USD 4.74, while Jazz Pharmaceuticals PLCJAZZ's earnings per share (EPS) for the previous quarter was USD 3.33. EPS for the next quarter is expected at USD 6.18.
What is the analyst rating for Jazz Pharmaceuticals PLC?
Based on the ratings of Jazz Pharmaceuticals PLC's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.